title: The prevalence of HTLV-III/LAV antibodies among intravenous drug users attending treatment programs in California: a preliminary report.
authors.forename: N
authors.initials: N
authors.lastname: Levy
authors.forename: J R
authors.initials: JR
authors.lastname: Carlson
authors.forename: S
authors.initials: S
authors.lastname: Hinrichs
authors.forename: N
authors.initials: N
authors.lastname: Lerche
authors.forename: M
authors.initials: M
authors.lastname: Schenker
authors.forename: M B
authors.initials: MB
authors.lastname: Gardner
mesh_terms: D000163:Acquired Immunodeficiency Syndrome / Q000453:epidemiology / Q000635:transmission; D000914:Antibodies, Viral / Q000032:analysis*; D002140:California; D015483:HIV Antibodies; D006801:Humans; D007275:Injections, Intravenous / Q000009:adverse effects; D019966:Substance-Related Disorders / Q000628:therapy
chemical_list: D000914:Antibodies, Viral; D015483:HIV Antibodies